BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that focuses on developing medicines for genetic diseases. A key product for the company is its drug, BEYONTTRA™ (acoramidis), which is designed to treat a heart condition known as transthyretin amyloid cardiomyopathy (ATTR-CM). BridgeBio Pharma operates in a field with other companies developing treatments for rare diseases.
On May 8, 2026, investment firm Bernstein showed increased confidence in BridgeBio Pharma by raising its price target to $114 from $100. The firm also maintained its Outperform rating on the stock. This rating suggests that Bernstein expects the stock to perform better than the overall market. At the time, BridgeBio Pharma was trading at $67.45 per share.
This positive outlook follows strong financial results. In its first quarter of 2026, BridgeBio Pharma reported revenues of approximately $195 million, which was over 8% higher than what analysts expected. This revenue is a significant increase from the $117 million reported in the same quarter of the previous year, showing strong revenue growth.
The company's operational success also supports this view. As highlighted by GlobeNewswire, BridgeBio Pharma's drug BEYONTTRA™ recently received approval in Brazil. This approval is based on a study showing the drug reduced mortality and cardiovascular hospitalizations by 42%. BEYONTTRA™ is now approved in major markets including the U.S., E.U., and Japan.
Despite its revenue growth, the company reported a quarterly loss of $0.84 per share, as noted by Zacks. However, this is an improvement from the loss of $0.88 per share from the same period a year ago. The company has a market capitalization of about $13.08 billion, with its stock trading between $31.77 and $84.94 over the past year.
